What pharma needs to do to keep up with the rise in value-based care.
Jenn Szekely
Advertisement
President, Coley Porter Bell
Articles by Jenn Szekely
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
Before You Sign with a New Hub Vendor, Ask These Four Questions
4
FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer
5